Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01708174
First received: October 11, 2012
Last updated: October 7, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2016
  Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)